Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Issue 1 (January 2015) - Falantes, Jose
Highlights Two scores identify lower-risk patients with survival similar to high-risk patients. Achieving response to azacitidine in these patients appears to impact on survival. Thrombocytopenia is the most important prognostic parameter in lower-risk MDS. This analysis supports a prospective intervention in these poor risk patients.